A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

Xiangyang Chi,Renhong Yan,Jun Zhang,Guanying Zhang,Yuanyuan Zhang,Meng Hao,Zhe Zhang,Pengfei Fan,Yunzhu Dong,Yilong Yang,Zhengshan Chen,Yingying Guo,Jinlong Zhang,Yaning Li,Xiaohong Song,Yi Chen,Lu Xia,Ling Fu,Lihua Hou,Junjie Xu,Changming Yu,Jianmin Li,Qiang Zhou,Wei Chen
DOI: https://doi.org/10.1126/science.abc6952
IF: 56.9
2020-08-07
Science
Abstract:Hitting SARS-CoV-2 in a new spot A key target for therapeutic antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the spike protein, a trimeric protein complex with each monomer comprising an S1 and an S2 domain that mediate binding to host cells and membrane fusion, respectively. In addition to the receptor binding domain (RBD), S1 has an N-terminal domain (NTD). In searching for neutralizing antibodies, there has been a focus on the RBD. Chi et al. isolated antibodies from 10 convalescent patients and identified an antibody that potently neutralizes the virus but does not bind the RBD. Cryo–electron microscopy revealed the epitope as the NTD. This NTD-targeting antibody may be useful to combine with RBD-targeting antibodies in therapeutic cocktails. Science , this issue p. 650
multidisciplinary sciences
What problem does this paper attempt to address?
According to the provided information, the title of this paper is "A neutralizing human antibody binds to the N - terminal domain of the Spike protein of SARS - CoV - 2", which was published by Junjie Xu et al. in the "Science" magazine on June 22, 2020. ### Problems the paper attempts to solve The main research questions of this paper are: 1. **Identify and characterize human antibodies that can effectively neutralize the SARS - CoV - 2 virus**: Researchers aim to find antibodies that can specifically bind to and inhibit the function of the Spike protein of the SARS - CoV - 2 virus. In particular, they focus on how these antibodies bind to the N - terminal domain (NTD) of the Spike protein and explore their role in preventing the virus from infecting cells. 2. **Understand the mechanism of interaction between antibodies and the viral Spike protein**: Through structural biology and biochemistry methods, researchers hope to reveal how antibodies precisely recognize and bind to specific regions of the Spike protein, thus providing insights at the molecular level, which is helpful for the development of more effective vaccines and therapeutic drugs. 3. **Evaluate the potential clinical applications of neutralizing antibodies**: In addition to basic research, this study also aims to evaluate whether the discovered neutralizing antibodies can be used as potential therapeutic tools for preventing or treating COVID - 19 infection. ### Formula representation Although this paper is mainly experimental and descriptive, some of the concepts involved can be represented by formulas, such as the affinity constant \(K_d\) (dissociation constant) of antigen - antibody binding: \[K_d=\frac{[A][B]}{[AB]}\] where: - \( [A]\) represents the concentration of free antigen, - \( [B]\) represents the concentration of free antibody, - \( [AB]\) represents the concentration of the antigen - antibody complex. This formula can help understand the binding strength and stability between antibodies and the Spike protein. In conclusion, this paper provides important scientific basis for the development of effective COVID - 19 treatment methods by identifying and characterizing neutralizing antibodies against the N - terminal domain of the SARS - CoV - 2 Spike protein.